REGULATORY
No tDCS device holds FDA approval for focus — anywhere. Here is what CDSCO licensing and IEC 60601-1-2 certification actually mean, what they do not mean, and how to judge any brain-stimulation device on evidence instead.
Loading…
Continue Reading
Related articles from the knowledge base
THE MECHANISM
It doesn't fire neurons. It changes who does.
8 min read
TECHNOLOGY CHOICE
Why We Chose tDCS Over Every Other Brain Technology.
12 min read
TECHNOLOGY
What Is Closed-Loop tDCS, and Why It Changes Everything
12 min read
SLEEP SCIENCE
The Cognitive Era of Wearables: Beyond Fitness, Into the Brain
9 min read
OUR STORY
Why Seven Years of Chasing Neurofeedback Led Us to Build Something Completely Different
12 min read
FREQUENTLY ASKED
No. Sychedelic is not FDA-approved or FDA-cleared. It is a consumer wellness device, and the FDA does not approve any tDCS product for focus or cognitive enhancement. The brand instead cites Indian CDSCO licensing and IEC 60601-1-2 EMC certification.
Yes, but only one, and only for depression. In December 2025 the FDA approved the Flow Neuroscience FL-100 tDCS device for moderate-to-severe major depressive disorder, by prescription. No tDCS device is FDA approved for focus, attention, or productivity.
It means a device holds the relevant licence to be made, imported, or sold in India under the Medical Devices Rules, 2017, administered by the Central Drugs Standard Control Organisation. Higher-risk devices such as neurostimulators are licensed centrally by CDSCO.
No. CDSCO is India's national regulator and plays a role similar to the FDA, but the two are separate bodies with different standards and scopes. A CDSCO licence does not mean a device is FDA-approved, and the reverse is also true.
IEC 60601-1-2 certifies electromagnetic compatibility for medical electrical equipment. It confirms the device neither causes nor is unduly disrupted by electromagnetic interference. It does not certify that the therapy works.
No. It addresses electromagnetic compatibility only. Overall basic safety is covered by the parent standard IEC 60601-1, and stimulator-specific safety by IEC 60601-2-10. Effectiveness is not addressed by any of these standards.
At conventional intensities of 4 mA or less and durations of 40 minutes or less, the published evidence shows a strong safety profile, with no serious adverse effects reported across more than 33,200 sessions (Bikson et al., 2016, PMID 27372845). Minor side effects such as tingling, itching, redness, and mild headache are common.
Yes, usually mild and temporary. The most common are skin tingling or itching under the electrodes, brief redness, a prickling sensation, headache, and fatigue. Good electrode preparation reduces them. Serious adverse effects have not been reported under conventional protocols.
Not definitively. tDCS is studied across many uses and its safety data is reassuring, but whether it reliably improves focus in healthy people remains an active area of research and debate. Treat strong "guaranteed focus" claims with caution, from any brand.
As a consumer wellness device, Sychedelic is sold directly to buyers without a prescription. By contrast, the FDA-approved tDCS depression device is prescription-only, because it is regulated as a medical treatment for a diagnosed condition.
Yes. The FDA approves or clears only products marketed as medical devices for medical claims. Consumer wellness products that make no disease claims are sold lawfully without FDA approval, in the US and abroad, although that also means no regulator has independently vetted their benefit claims.
Ask for specifics. Request the CDSCO licence number and device class, confirm the standard is written correctly as IEC 60601-1-2, and check that any clinical figures cite their original source. Reputable manufacturers can document the claims behind their badges.
THE INSTRUMENT
Sychedelic combines everything described in this article into one 20-minute protocol.